Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMIDS) USING SYSTEMS APPROACHES
2024-518011-19-00Phase 2Withdrawn
- Sponsor
- Cardiff University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 2 trial of leuprolide and tocilizumab in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), sponsored by Cardiff University. Primary endpoint: Disease remission at week 24. Planned start Jul 2025; status: withdrawn.
02
Drugs
leuprolidetocilizumab
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2024-518011-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518011-19-00.